Download PDF
Semin Liver Dis 2011; 31(4): 399-409
DOI: 10.1055/s-0031-1297928
© Thieme Medical Publishers

The Era of Direct-Acting Antivirals Has Begun: The Beginning of the End for HCV?

Marie-Louise Vachon1 , Douglas T. Dieterich2
  • 1Research Center in Infectious Diseases, Centre Hospitalier Universitaire de Quebec and Laval University, Quebec, Canada
  • 2Division of Liver Diseases, Department of Medicine, The Mount Sinai School of Medicine, New York, New York
Further Information

Publication History

Publication Date:
21 December 2011 (online)

    Permissions and Reprints

ABSTRACT

The year 2011 marks the dawn of the new era of direct-acting antivirals for hepatitis C. For the first time since 1998, the U.S. Food and Drug Administration approved two new antiviral drugs for the treatment of chronic hepatitis C virus genotype 1. Dual therapy with pegylated interferon and ribavirin is no longer the standard of care for genotype 1. The new treatment paradigm includes one direct-acting antiviral, a protease inhibitor, in combination with pegylated interferon and ribavirin. This combination nearly doubles the chances of response to treatment, but at the cost of increased toxicity. Many agents with different mechanisms of action and improved safety profiles are in clinical development. The holy grail of HCV treatment is an all oral, interferon-free treatment. The ideal regimen will be potent, well tolerated, with minimal drug–drug interactions and once daily. This article covers new concepts of treatment of hepatitis C with DAAs and gives an overview of the recent highlights in direct-acting antiviral development.

KEYWORDS

Hepatitis C - treatment - direct-acting antivirals

REFERENCES

  • 1 Kieffer T L, Kwong A D, Picchio G R. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).  J Antimicrob Chemother. 2010;  65 (2) 202-212
    Google Scholar
  • 2 Moradpour D, Penin F, Rice C M. Replication of hepatitis C virus.  Nat Rev Microbiol. 2007;  5 (6) 453-463
    Google Scholar
  • 3 Pawlotsky J M, Chevaliez S, McHutchison J G. The hepatitis C virus life cycle as a target for new antiviral therapies.  Gastroenterology. 2007;  132 (5) 1979-1998
    Google Scholar
  • 4 Ogata N, Alter H J, Miller R H, Purcell R H. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus.  Proc Natl Acad Sci U S A. 1991;  88 (8) 3392-3396
    Google Scholar
  • 5 Bartels D J, Zhou Y, Zhang E Z et al.. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.  J Infect Dis. 2008;  198 (6) 800-807
    Google Scholar
  • 6 Pawlotsky J M. Hepatitis C virus genetic variability: pathogenic and clinical implications.  Clin Liver Dis. 2003;  7 (1) 45-66
    Google Scholar
  • 7 Susser S, Welsch C, Wang Y et al.. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.  Hepatology. 2009;  50 (6) 1709-1718
    Google Scholar
  • 8 Sarrazin C, Kieffer T L, Bartels D et al.. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.  Gastroenterology. 2007;  132 (5) 1767-1777
    Google Scholar
  • 9 Wagner F, Thompson R, Kantaridis C et al.. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients.  Hepatology. 2011;  54 (1) 50-59
    Google Scholar
  • 10 McCown M F, Rajyaguru S, Kular S, Cammack N, Nájera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.  Antimicrob Agents Chemother. 2009;  53 (5) 2129-2132
    Google Scholar
  • 11 Lee S S, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.  Antivir Ther. 2008;  13 (Suppl 1) 9-16
    Google Scholar
  • 12 Jacobson I M, McHutchison J G, Dusheiko G ADVANCE Study Team et al. Telaprevir for previously untreated chronic hepatitis C virus infection.  N Engl J Med. 2011;  364 (25) 2405-2416
    Google Scholar
  • 13 Poordad F, McCone Jr J, Bacon B R SPRINT-2 Investigators et al. Boceprevir for untreated chronic HCV genotype 1 infection.  N Engl J Med. 2011;  364 (13) 1195-1206
    Google Scholar
  • 14 Sulkowski M S, Ceasu E, Asselah T et al.. SILEN-C1: sustained virologic response (SVR) and safety of BI 201335 combined with peginterferon alfa-2a and ribavirin (P/R) in treatment-naive patients with chronic genotype 1 HCV.  J Hepatol. 2011;  54 (Suppl 1) S27
    Google Scholar
  • 15 Zeuzem S, Andreone P, Pol S REALIZE Study Team et al. Telaprevir for retreatment of HCV infection.  N Engl J Med. 2011;  364 (25) 2417-2428
    Google Scholar
  • 16 Lin T I, Lenz O, Fanning G et al.. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.  Antimicrob Agents Chemother. 2009;  53 (4) 1377-1385
    Google Scholar
  • 17 Fried M W, Buti M, Dore G J et al.. Efficacy and safety of TMC435 in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 1 HCV patients: 24 week interim results from the PILLAR study.  Hepatology. 2010;  52 (Suppl 1) 107A
    Google Scholar
  • 18 Huisman M T, Snoeys J, Monbaliu J et al.. In vitro studies investigating the mechanisms of interaction between TMC435 and hepatic transporters.  Hepatology. 2010;  52 (Suppl 1) 461A
    Google Scholar
  • 19 Sulkowski M S, Bourliere M, Bronowicki J P et al.. SILEN-C2: sustained virologic response (SVR) and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in chronic HCV genotype-1 patients with non-response to P/R.  J Hepatol. 2011;  24 (Suppl 1) S30
    Google Scholar
  • 20 Sane R, Podila L, Mathur A et al.. Mechanisms of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI201335.  J Hepatol. 2011;  54 (Suppl 1) S488
    Google Scholar
  • 21 Detishin V, Haazen R, Hooijmaijers R et al.. Final results of the pharmacokinetics, efficacy, safety/tolerability of 400 and 600 mg once-daily dosing of ACH-1625 (HCV NS3 protease inhibitor) in HCV genotype 1.  J Hepatol. 2011;  54 (Suppl 1) S186-S187
    Google Scholar
  • 22 Forestier N, Larrey D, Marcellin P et al.. Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.  J Infect Dis. 2011;  204 (4) 601-608
    Google Scholar
  • 23 Gane E J, Rouzier R, Stedman C et al.. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.  J Hepatol. 2011;  55 (5) 972-979
    Google Scholar
  • 24 Terrault N, Cooper C, Balart L A et al.. Phase II randomized, partially blind, parallel-group study of oral danoprevir (RG7227) with PegIFN alfa-2a (PEGASYS) plus ribavirin (COPEGUS) in treatment-naive genotype 1 patients with CHC: results of planned week 12 interim analysis of the ATLAS study.  Hepatology. 2010;  52 (Suppl 1) 73A
    Google Scholar
  • 25 Rouzier R, Larrey D, Gane E J et al.. Danoprevir plus low-dose ritonavir (DNV/R) in combination with peginterferon alfa-2a (40KD) plus ribavirin (PEGIFN-2a/RBV) in previous null responders.  J Hepatol. 2011;  54 (Suppl 1) S28
    Google Scholar
  • 26 Lok A S, Gardiner D, Lawitz E et al.. Quadruple therapy with BMS-790052, BMS-650032 and Peg-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders.  J Hepatol. 2011;  54 (Suppl 1) S536
    Google Scholar
  • 27 Mcphee F, Hernandez D, Yu F et al.. Charcterization of virologic escape in HCV genotype 1 null responders receiving a combination of the NS3 protease inhibitor BMS-650032 and NS5A inhibitor BMS-790052.  J Hepatol. 2011;  54 (Suppl 1) S28-S29
    Google Scholar
  • 28 Foster G R, Buggisch P, Marcellin P et al.. Four-week treatment with GS-9256 and tegobuvir (GS-9190) ± RBV ± PEG, results in enhanced viral suppression of follow-up PEG/RBV therapy, in genotype 1a/1b HCV patients.  J Hepatol. 2011;  54 (Suppl 1) S172
    Google Scholar
  • 29 Wong K A, Bae A, Ku K et al.. Genotypic and phenotypic characterization of HCV resistance from a multiple dose clinical trial of GS-9451, a novel NS3 protease inhibitor.  J Hepatol. 2011;  54 (Suppl 1) S493
    Google Scholar
  • 30 Tong L, Mwangi J, Roy A et al.. In vitro studies on the potential for the hepatitis C virus protease inhibitors GS-9256 and GS-9451 to affect bilirubin elimination.  J Hepatol. 2011;  54 (Suppl 1) S487
    Google Scholar
  • 31 Lawitz E, Rodriguez-Torres M, Denning J et al.. Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA <LOD at day 14: first purine/pyrimidine clinical combination cata (The NUCLEAR Study).  J Hepatol. 2011;  54 (Suppl 1) S543
    Google Scholar
  • 32 Lalezari J, Lawitz E, Rodriguez-Torres M et al.. Once daily PSI-7977 plus PEGIFN/RBV in a phase 2b trial: rapid virologic suppression in treatment-naïve patients with GT2/GT3.  J Hepatol. 2011;  54 (Suppl 1) S28
    Google Scholar
  • 33 McCown M F, Rajyaguru S, Le Pogam S et al.. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.  Antimicrob Agents Chemother. 2008;  52 (5) 1604-1612
    Google Scholar
  • 34 Lawitz E, Rodriquez-Torres M, Rustgi V K et al.. Safety and antiviral activity of ANA598 in combination with pegylated interferon α2A plus ribavirin in treatment-naïve genotype 1 chronic HCV patients.  J Hepatol. 2010;  52 (Suppl 1) S467
    Google Scholar
  • 35 Gao M, Nettles R E, Belema M et al.. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.  Nature. 2010;  465 (7294) 96-100
    Google Scholar
  • 36 Tellinghuisen T L, Foss K L, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein.  PLoS Pathog. 2008;  4 (3) e1000032
    Google Scholar
  • 37 Qiu D, Lemm J A, O’Boyle II D R et al.. The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization.  J Gen Virol. 2011;  92 (Pt 11) 2502-2511
    Google Scholar
  • 38 Nettles R E, Gao M, Bifano M et al.. Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.  Hepatology. 2011;  Epub ahead of print
    Google Scholar
  • 39 Fridell R A, Wang C, Sun J H et al.. Genotypic and phenotypic analysis of variants resistant to HCV NS5A replication complex inhibitor BMS-790052: in vitro and in vivo correlations.  Hepatology. 2011;  Epub ahead of print
    Google Scholar
  • 40 Fridell R A, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.  Antimicrob Agents Chemother. 2010;  54 (9) 3641-3650
    Google Scholar
  • 41 Crabbé R, Vuagniaux G, Dumont J M, Nicolas-Métral V, Marfurt J, Novaroli L. An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C.  Expert Opin Investig Drugs. 2009;  18 (2) 211-220
    Google Scholar
  • 42 Flisiak R, Feinman S V, Jablkowski M et al.. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.  Hepatology. 2009;  49 (5) 1460-1468
    Google Scholar
  • 43 Flisiak R, Pawlotsky J, Crabbé R et al.. Once daily alisporivir (Deb025) plus PEGIFNalfa2a/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment naïve patients.  J Hepatol. 2011;  54 (Suppl 1) S2
    Google Scholar
  • 44 Coelmont L, Hanoulle X, Chatterji U et al.. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.  PLoS ONE. 2010;  5 (10) e13687
    Google Scholar

Marie-Louise VachonM.D. M.Sc. 

Research Center in Infectious Diseases, Centre Hospitalier Universitaire de Quebec and Laval University, CHUL

Rm. S-796, 2705 Blvd. Laurier, Quebec City, Quebec, Canada G1V 4G2

Email: Marie-Louise.Vachon@mail.chuq.qc.ca

      >